Prasugrel: Clinical development and therapeutic application.

Published

Journal Article (Review)

Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the management of patients with acute coronary syndromes and following percutaneous coronary intervention. Despite the proven benefits, clear limitations of clopidogrel exist. Prasugrel is a third-generation thienopyridine antiplatelet agent with pharmacologic characteristics that overcome some of the limitations of clopidogrel, but at the expense of increased bleeding. The promising results seen with prasugrel in large, randomized trials led to its recent approval by the US Food and Drug Administration for reducing thrombotic cardiovascular events in patients with acute coronary syndromes managed with percutaneous coronary intervention. This article will review the limitations of standard antiplatelet therapy and discuss the clinical application of prasugrel.

Full Text

Duke Authors

Cited Authors

  • Guerra, DR; Tcheng, JE

Published Date

  • November 2009

Published In

Volume / Issue

  • 26 / 11

Start / End Page

  • 999 - 1011

PubMed ID

  • 20020231

Pubmed Central ID

  • 20020231

Electronic International Standard Serial Number (EISSN)

  • 1865-8652

International Standard Serial Number (ISSN)

  • 0741-238X

Digital Object Identifier (DOI)

  • 10.1007/s12325-009-0081-y

Language

  • eng